首页> 外文期刊>Financial management >Earnings and Equity Valuation in the Biotech Industry: Theory and Evidence
【24h】

Earnings and Equity Valuation in the Biotech Industry: Theory and Evidence

机译:生物技术产业的收益和股权估值:理论和证据

获取原文
获取原文并翻译 | 示例
           

摘要

We examine how the price-earnings relation varies with the uncertainty about and the quality of a firm's investments. We develop a real option valuation framework to capture investment and abandonment options in the research-intensive biotechnology industry. We hypothesize that the price-earnings relation will be V-shaped and change over the firm's life cycle. We also show how nonfinancial information affects the pricing of earnings. Our empirical findings are based on a sample of 301 biotechnology firms that made IPOs between 1980 and 2000, and are generally consistent with our predictions.
机译:我们研究了市盈率如何随公司投资的不确定性和质量而变化。我们开发了一个实物期权估值框架,以捕获研究密集型生物技术行业的投资和放弃期权。我们假设市盈率关系将呈V形,并且会在企业的整个生命周期内发生变化。我们还将展示非财务信息如何影响收益定价。我们的经验发现是基于1980年至2000年间301家进行IPO的生物技术公司的样本,并且总体上与我们的预测相符。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号